DiagnaMed’s BRAIN AGE® Brain Health AI Platform Accomplishes Clinical Validation Milestone with Peer-Reviewed Paper TORONTO, April 25, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI,...

International Consortium Publishes Comprehensive Roadmap for the Clinical Implementation of OGM in Hematological Malignancy Applications Framework was co-authored by an international consortium made up of 18 cancer researchers Publication includes researchers’ recommendations for laboratories planning to adopt optical genome mapping...

Juva Life Brings Bold Outlook for the New Year VANCOUVER, British Columbia, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a premier California based...

Oncotelic Reports Clinical Validation of Drug Induce Xenogenization (DIX) For Treatment of Glioblastoma and Pancreatic Cancer (PC) Phase 2 Clinical Data Presented at ASCO-SITC Clinical Immuno-Oncology SymposiumXenogenization through chemotherapy-induced genetic mutations (alkylating agents such as temozolomide) or drug-induced...